ONL DRC A Phase 1 Open-Label, Dose Escalation Study to Assess the Safety and Tolerability of Intravitreal ONL1204 in Patients with Macula-off, Rhegmatogenous Retinal Detachment

Administered By

Awarded By

Contributors

Start/End

  • September 20, 2019 - March 31, 2021